Rectal Drug Delivery Formulation Services for Preclinical Development
Rectal drug delivery is a route of administration that delivers small molecules and sustained-release therapeutics directly into the rectal lumen through drops, gels, enemas, and sustained release systems, offering an alternative to oral and injectable delivery when a candidate’s absorption profile, stability, or patient population calls for it. Oral drug delivery is one of the drug delivery routes, Integral BioSystems supports for biotechnology and pharmaceutical companies advancing preclinical candidates toward IND-enabling studies. Contact us to discuss a formulation strategy for your active pharmaceutical ingredient (API).
Rectal Route of Drug Administration Considerations
The rectal route is often considered when a therapeutic candidate faces obstacles that limit other delivery options, including poor oral bioavailability, extensive first-pass hepatic metabolism, degradation in the gastric environment, or a patient population unable to tolerate oral or injectable dosing. Because venous drainage from the lower rectum bypasses the hepatic portal system, rectal administration can reduce first-pass metabolism for some therapeutics relative to oral dosing, an effect that depends on where in the rectum absorption occurs.
Selecting a formulation approach for the rectal route starts with the location of the target receptor, whether it is a surface receptor local to the rectal mucosa or an intracellular target requiring deeper tissue penetration, and the physicochemical characteristics of the therapeutic itself. Relevant properties include pKa, log P, stability at the alkaline pH of the rectal environment, approximately 7.4 to 7.8, solubility, molecular weight, and charge. Each of these factors determines which rectal delivery modality is a realistic formulation path and which is not.
Formulation Strategies for Rectal Administration
For a hydrophilic small molecule or biologic drug, a chemically compatible, hydrophilic, mucoadhesive carrier is the typical starting point. The drug product can be delivered as a 2 to 5 mL fluid to achieve full coverage of the rectal space, formulated as an aqueous solution of a bioadhesive polymer that enhances residence time at the absorption surface. A uni-dose rectal gel, preloaded into a syringe for ease of administration, is another option worth evaluating early in development.
Beyond gels and enemas, the rectal route supports a wider set of dosage forms depending on the molecule and the desired release profile, including suppositories, suspensions, microspheres, nanoparticle systems, liposomes, tablets, and hydrogels. Integral BioSystems’ PLGA microsphere development services extend directly to rectal programs that call for a sustained release profile.
Suppositories are generally not a fit for hydrophilic or labile actives, because the manufacturing process requires high temperatures to melt the wax base for drug incorporation, conditions that can degrade sensitive molecules. For actives with limited aqueous solubility, Integral BioSystems’ cyclodextrin formulation development services are one option evaluated to improve compatibility with an aqueous rectal carrier.
Storage conditions, refrigerated or room temperature, depend on the stability profile of the drug substance. Both an enema and a rectal gel are typically developed in parallel early on, with the final formulation selected based on pharmacokinetics, product stability, ease of use, and patient compliance. A rectal gel generally supports higher patient compliance than an enema when dosing is frequent.
Depending on the stability of the drug, storage conditions will be either refrigerated or RT. Both the enema and the rectal gel should be developed; the final formulation should be selected based on pharmacokinetics, drug product stability, ease of use and marketing considerations. A rectal gel clearly would have a higher patient compliance than an enema, if dose administration is frequent.
Rectal Absorption and Bioavailability Factors
The absorption surface of the rectum ranges between approximately 0.02 and 0.05 m², coated by a viscous rectal fluid that functions as the rectal mucosa and offers very low buffer capacity. Because of this, the carrier for a rectal drug product must be miscible with the rectal mucosa and able to permeate it to reach the target receptor, whether that receptor sits at the mucosal surface or deeper in the tissue.
Extending the residence time of the therapeutic at the absorption surface is often the deciding factor in bioavailability, particularly for hydrophilic drugs that do not readily cross the mucosal barrier on their own. The carrier must remain compatible with the drug substance and ideally persist in the tissue space as long as possible to maximize the absorption window, the same design logic that drives bioadhesive polymer selection in the formulation strategies above.
Rectal Drug Delivery FAQs
Which Drug Candidates Are Good Formulation Fits for the Rectal Route?
Candidates with poor oral bioavailability, gastric instability, or extensive first-pass hepatic metabolism are frequently good fits, as are hydrophilic small molecules and biologics that require a mucoadhesive, aqueous carrier rather than a suppository base. Actives that are labile at elevated temperature are also better suited to a gel or enema formulation, since suppository manufacturing requires melting a wax base that can degrade sensitive molecules.
Does Rectal Administration Avoid First-Pass Liver Metabolism?
Partially, and the effect depends on where in the rectum absorption occurs. Drug absorbed through the lower and middle rectal veins drains into the systemic circulation and bypasses the liver, while drug absorbed higher in the rectum drains through the superior rectal vein into the portal system and is subject to first-pass metabolism. On average, roughly half of an absorbed dose is estimated to bypass hepatic first-pass metabolism by this route.
What Formulation Challenges Are Unique to the Rectal Route?
The rectal environment has a small fluid volume, an alkaline pH of approximately 7.4 to 7.8, and very low buffer capacity, which constrains excipient and pH-modifier selection. Absorption is also subject to interpatient variability, since rectal retention of the dose is under a degree of voluntary control, and premature expulsion can reduce the effective exposure.
Can Biologics Be Delivered Through the Rectal Route?
Proteins and peptides can be formulated for rectal delivery, though molecular weight and charge become limiting factors, since larger, more polar macromolecules cross the rectal mucosa less readily than small molecules. Early feasibility screening against these physicochemical properties is an important step before committing to a rectal delivery strategy for a biologic candidate.
When Should a Program Consider Rectal Delivery Over Other Routes?
Rectal delivery is worth evaluating when oral bioavailability is poor, when intravenous dosing is impractical for outpatient or chronic use, when the treatment goal is localized to the lower gastrointestinal tract, or when the target patient population, such as pediatric patients or those experiencing nausea and vomiting, cannot reliably tolerate oral dosing.
CRO Services for Rectal Drug Delivery
Integral BioSystems is a contract research organization that provides quality services specializing in pre-clinical stage pharmaceutical research and development at a competitive price and turnaround time. Learn more about our CRO services >
Ready to revolutionize rectal drug delivery with tailored formulations designed for optimal efficacy and patient compliance? Contact Integral BioSystems today to develop a customized solution that meets the unique needs of your API. Take the next step towards advancing rectal drug delivery with Integral BioSystems as your trusted partner!
What our
clients say
Some of our amazing customers
